Fineline Cube

Follow:
14420 Articles
Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
CompanyDeals

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite

ModeX Therapeutics Partners With Regeneron on Multispecific Antibody Platform
CompanyDeals

ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
CompanyDeals

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
CompanyDrug

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
CompanyDrug

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
CompanyDeals

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal

Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
CompanyDeals

Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
Policy / Regulatory

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue

Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
CompanyDeals

Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million

Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma
CompanyDrug

Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma

Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma
CompanyDeals

Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody
CompanyDrug

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody